ConductScience.org, home

Paper6138375

Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism.

Packer M. J Am Coll Cardiol, 1983. Cited by 148 papers, by iCite.

Cite this record

ConductScience Library. Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. Papers, record 6138375. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6138375

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism.
PubMed
Journal
J Am Coll Cardiol
PubMed
Year
1983
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S., Review
PubMed
Citations, by iCite
148
iCite
Relative citation ratio, by iCite
7.4
iCite
Revised in PubMed
2019-07-08
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Packer MM

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiotonic AgentsMajor topic
Heart FailureMajor topic
Vasodilator AgentsMajor topic
Administration, Oral
Calcium Channel Blockers
Chronic Disease
Drug Evaluation
Drug Tolerance
Humans
Neurotransmitter Agents

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R23-HL-25055NHLBI NIH HHSUnited StatesR23HL025055PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 148 citations.

PMIDTitleJournalYearIn PapersSource
25218145Mitogen-activated protein kinase kinase 1/2 inhibition and angiotensin II converting inhibition in mice with cardiomyopathy caused by lamin A/C gene mutation.Biochem Biophys Res Commun2014https://conductscience.org/library/papers/25218145PubMed
6532481The role of digitalis in the future.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6532481PubMed
3887015[Modification of organ perfusion by calcium blocker and converting enzyme inhibitor in the conscious rat with heart failure].Klin Wochenschr1985https://conductscience.org/library/papers/3887015PubMed
3784463[Calcium antagonists in heart failure?].Klin Wochenschr1986https://conductscience.org/library/papers/3784463PubMed
3758138The search of an ideal oral positive inotropic agent.Eur J Clin Pharmacol1986https://conductscience.org/library/papers/3758138PubMed
3722083Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure.Heart Vessels1986https://conductscience.org/library/papers/3722083PubMed
3569109The future role of inotropic drugs.Drugs1986https://conductscience.org/library/papers/3569109PubMed
3552590The role of vasodilator therapy in the treatment of severe chronic heart failure.Drugs1986https://conductscience.org/library/papers/3552590PubMed
3281740Congestive heart failure.CMAJ1988https://conductscience.org/library/papers/3281740PubMed
3203040Sustained haemodynamic effects of felodipine in patients with chronic cardiac failure.Br J Clin Pharmacol1988https://conductscience.org/library/papers/3203040PubMed
3167315Proceedings of the British Pharmacological Society. Ireland, 6th-8th July, 1988. Abstracts.Br J Pharmacol1988https://conductscience.org/library/papers/3167315PubMed
3154305Angiotensin inhibitors and other vasodilators with special reference to congestive heart failure.Cardiovasc Drugs Ther1987https://conductscience.org/library/papers/3154305PubMed
3120955Mortality in congestive heart failure: effects of vasodilator therapy.Br Med J (Clin Res Ed)1987https://conductscience.org/library/papers/3120955PubMed
2994697
Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients.
Br Heart J1985https://conductscience.org/library/papers/2994697PubMed
2656046Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.Clin Pharmacokinet1989https://conductscience.org/library/papers/2656046PubMed
2653391Effect of flosequinan on exercise capacity and symptoms in severe heart failure.Br Heart J1989https://conductscience.org/library/papers/2653391PubMed
2598980Is addition of prazosin beneficial in chronic heart failure refractory to angiotensin converting enzyme inhibition?Eur J Clin Pharmacol1989https://conductscience.org/library/papers/2598980PubMed
2537095Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure.Br Heart J1989https://conductscience.org/library/papers/2537095PubMed
2487535Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.Cardiovasc Drugs Ther1989https://conductscience.org/library/papers/2487535PubMed
2487522New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan.Cardiovasc Drugs Ther1989https://conductscience.org/library/papers/2487522PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6138375

GET https://conductscience.org/api/papers/v1/6138375/cited_by?page=2